Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H2 2019’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome)

– The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neuromyelitis Optica (Devic’s Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Neuromyelitis Optica (Devic’s Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Accendatech Au Pty Ltd

Ahead Therapeutics SL

Alexion Pharmaceuticals Inc

Apsara Therapeutics

Bio-Thera Solutions Ltd

Biogen Inc

Bionure Farma SL

Boston Pharmaceuticals Inc

Chord Therapeutics Sarl

Chugai Pharmaceutical Co Ltd

Cour Pharmaceuticals Development Co Inc

Endece LLC

EnhanX Biopharm Inc

Ferring International Center SA

H. Lundbeck AS

HanAll Biopharma Co Ltd

ImCyse SA

Imstem Biotechnology Inc

LFB SA

Mitsubishi Tanabe Pharma Corp

NovelMed Therapeutics Inc

Orion BioScience Inc

Thelial Technologies SA

Tolerion Inc

Viela Bio Inc

Yantai RC-Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Neuromyelitis Optica (Devic’s Syndrome) Overview 5

Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Development 6

Neuromyelitis Optica (Devic’s Syndrome) Therapeutics Assessment 14

Neuromyelitis Optica (Devic’s Syndrome) Companies Involved in Therapeutics Development 22

Neuromyelitis Optica (Devic’s Syndrome) Drug Profiles 28

Neuromyelitis Optica (Devic’s Syndrome) Dormant Projects 99

Neuromyelitis Optica (Devic’s Syndrome) Discontinued Products 100

Neuromyelitis Optica (Devic’s Syndrome) Product Development Milestones 101

Appendix 109

List of Tables

“List of Tables

Table 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 6: Products under Development by Universities/Institutes, H2 2019

Table 7: Number of Products by Stage and Target, H2 2019

Table 8: Number of Products by Stage and Mechanism of Action, H2 2019

Table 9: Number of Products by Stage and Route of Administration, H2 2019

Table 10: Number of Products by Stage and Molecule Type, H2 2019

Table 11: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Accendatech Au Pty Ltd, H2 2019

Table 12: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Ahead Therapeutics SL, H2 2019

Table 13: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Alexion Pharmaceuticals Inc, H2 2019

Table 14: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Apsara Therapeutics, H2 2019

Table 15: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Bio-Thera Solutions Ltd, H2 2019

Table 16: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Biogen Inc, H2 2019

Table 17: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Bionure Farma SL, H2 2019

Table 18: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Boston Pharmaceuticals Inc, H2 2019

Table 19: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Chord Therapeutics Sarl, H2 2019

Table 20: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019

Table 21: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Cour Pharmaceuticals Development Co Inc, H2 2019

Table 22: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Endece LLC, H2 2019

Table 23: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by EnhanX Biopharm Inc, H2 2019

Table 24: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Ferring International Center SA, H2 2019

Table 25: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by H. Lundbeck AS, H2 2019

Table 26: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by HanAll Biopharma Co Ltd, H2 2019

Table 27: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by ImCyse SA, H2 2019

Table 28: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Imstem Biotechnology Inc, H2 2019

Table 29: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by LFB SA, H2 2019

Table 30: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Table 31: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by NovelMed Therapeutics Inc, H2 2019

Table 32: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Orion BioScience Inc, H2 2019

Table 33: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Thelial Technologies SA, H2 2019

Table 34: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Tolerion Inc, H2 2019

Table 35: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Viela Bio Inc, H2 2019

Table 36: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019

Table 37: Neuromyelitis Optica (Devic’s Syndrome) – Dormant Projects, H2 2019

Table 38: Neuromyelitis Optica (Devic’s Syndrome) – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports